Olivier Lurette is an early-career researcher at Université de Moncton working squarely on mitochondrial biology, with two coherent research threads: (1) mitochondrial Src kinase signaling, and (2) α-synuclein–mitochondria interactions in Parkinson's disease. His bibliometric profile (7 papers, ~193–203 citations, h-index 4–5) reflects a compact but citation-efficient body of work .
The steep rise in citations (58 in 2025) is driven almost entirely by his first-author flagship study in Cell Death & Disease (94 citations), which used the optogenetic LIPA system to demonstrate that aggregated α-synuclein — but not soluble overexpressed α-syn — reduces mitochondrial content, lowers ATP and oxygen consumption rate, promotes Drp1-mediated fragmentation, and triggers ubiquitin-independent mitophagy requiring cardiolipin externalization via PLSCR3, with BNIP3L/FUNDC1 dispensable. Findings spanned HEK/HeLa/N2A cells, human iPSC-derived dopaminergic neurons, and mouse substantia nigra in vivo, typically with ~3 biological replicates and modest sample sizes .
His earlier mitochondrial-Src work — first in breast cancer aggressiveness (Cell Death & Disease, 41 citations) and later a mechanistic follow-up on Src regulation of mitochondrial morphology — shows technical breadth spanning kinase signaling, respirometry (Seahorse/Oroboros O2k), optogenetics, and confocal live imaging. Contributing authorships on a mtDNA damage review and a peroxisome/Zellweger study indicate collaborative range beyond core projects.
Verdict: a technically skilled, focused mitochondrial biologist with one high-impact mechanistic contribution and an accelerating citation curve; independent impact (post-PhD PI-level leadership) is not yet established from available data. Confidence: moderate — based on 7 papers and extracted metadata only; institution history, reviewer activity, and full CV gaps limit precision.
Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.